Director, Medical Writing

Hemab is building preventative treatments for serious, underserved bleeding disorders. These therapies are designed to work with the body's own biology and stop bleeds before they start, instead of treating them after they happen. We're patient-first, science-led and clinical-stage, with a pipeline that takes different scientific approaches to different patient needs. We went public via our 2026 IPO, and we're scaling across two homes: Cambridge, MA, USA, and Copenhagen, Denmark. The role As Director, Medical Writing, you will be dedicated to one of our compounds under clinical development, …